2 results
Approved WMOCompleted
The primary objectives of this study is:* To determine the safety and tolerability of rhHNS via ascending doses administered via a surgically implanted intrathecal drug device (IDDD) once monthly for 6 months, in patientswith MPS IIIA.The secondary…
Approved WMOCompleted
Primary ObjectivesDose Escalation Phase* To determine the maximum tolerated dose (MTD) of multiple ERY974 dosing schedules, including fixed dose schedules and an individual dose titration schedule, in patients with locally advanced or metastatic…